Author:
Kalantar zadeh Mina,Williamson Elizabeth M.
Publisher
Springer International Publishing
Reference47 articles.
1. Zhuge Y, Liu Y, Xie W et al (2019) Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol 34(4):634–642. https://doi.org/10.1111/jgh.14612
2. Neuman MG, Cohen L, Opris M, Nanau RM, Hyunjin J (2015) Hepatotoxicity of pyrrolizidine plkaloids. J Pharm Pharm Sci 18(4):825–843. https://doi.org/10.18433/j3bg7j
3. Chen J, Lü H, Fang L et al (2017) Detection and toxicity evaluation of pyrrolizidine alkaloids in medicinal plants Gynura bicolor and Gynura divaricata collected from different Chinese locations. Chem Biodivers 14(2):e1600221. https://doi.org/10.1002/cbdv.201600221
4. Xu J, Wang W, Yang X, Xiong A, Yang L, Wang Z (2019) Pyrrolizidine alkaloids: an update on their metabolism and hepatotoxicity mechanism. Liver Res 3(3-4):176–184. https://doi.org/10.1016/j.livres.2019.11.004
5. European Medicines Agency (2016) Public statement on contamination of herbal medicinal products/traditional herbal medicinal products with pyrrolizidine alkaloids. EMA/HMPC/328782/2016. https://www.ema.europa.eu/en/documents/public-statement/public-statement-contamination-herbal-medicinal-products/traditional-herbal-medicinal-products-pyrrolizidine-alkaloids_en.pdf. Accessed 3 Feb 2021